Chen Lepei, Gao Xiaoling
Departmentof Pharmacology and Chemical Biology, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai 200025, PR China.
Ther Deliv. 2017 Oct;8(10):915-928. doi: 10.4155/tde-2017-0023.
Stroke still represents one of the most common causes of death and disability worldwide. Acute ischemic stroke (AIS), caused by brain arterial occlusion resulting from a thrombus or embolus, is the most common form of stroke. However, current therapies in AIS are inadequate, and the only US FDA approved treatment is the thrombolytic drug Alteplase. Therefore, establishing effective therapeutic strategies for AIS is urgently needed. Using nanoparticle-based technologies to deliver neuroprotective agents to the ischemic area has attracted increasing attention of late. In this review, the important molecular pathological mechanisms in cerebral ischemia are briefly summarized, the potential of nanoparticulate drug-delivery systems for AIS intervention and recovery are introduced and problems in the medical application of nanoparticles will also be discussed.
中风仍然是全球范围内最常见的死亡和致残原因之一。急性缺血性中风（AIS）是由血栓或栓子导致脑动脉闭塞引起的，是中风最常见的形式。然而，目前AIS的治疗方法并不充分，美国食品药品监督管理局（FDA）唯一批准的治疗药物是溶栓药物阿替普酶。因此，迫切需要建立有效的AIS治疗策略。近年来，利用基于纳米颗粒的技术将神经保护剂输送到缺血区域引起了越来越多的关注。在这篇综述中，简要总结了脑缺血中重要的分子病理机制，介绍了纳米颗粒药物递送系统对AIS干预和恢复的潜力，还将讨论纳米颗粒在医学应用中的问题。
